OctoPlus N.V.
OctoPlus N.V., headquartered in the Netherlands, is a prominent player in the biopharmaceutical industry, specialising in the development of innovative drug delivery systems. Founded in 2000, the company has achieved significant milestones, including advancements in its proprietary technology platforms that enhance the efficacy and safety of therapeutic agents. With a focus on injectable formulations, OctoPlus offers unique services that cater to the specific needs of pharmaceutical companies, including formulation development and clinical trial support. Their expertise in complex drug delivery systems positions them as a trusted partner in the industry. Recognised for their commitment to quality and innovation, OctoPlus N.V. continues to strengthen its market position, contributing to the advancement of healthcare solutions globally.
DitchCarbon Score
How does OctoPlus N.V.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
OctoPlus N.V.'s score of 93 is higher than 96% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
OctoPlus N.V., headquartered in the Netherlands (NL), currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Dr. Reddy's Laboratories Limited, which influences its climate commitments and initiatives. As part of its corporate family relationship, OctoPlus N.V. inherits climate-related targets and performance metrics from Dr. Reddy's Laboratories Limited. This includes commitments to the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP), both of which are cascaded down from the parent company. However, specific reduction targets or achievements for OctoPlus N.V. have not been detailed. In the context of industry standards, OctoPlus N.V. aligns with broader climate initiatives through its association with Dr. Reddy's Laboratories Limited, which is actively engaged in reducing its carbon footprint and enhancing sustainability practices. The absence of direct emissions data suggests a need for further transparency and reporting in line with global climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 177,841,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 254,563,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
OctoPlus N.V. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
